🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dear Colleagues at #GU25 Honored to Present Our OncoAlert 🚨Faculty Petros Grivas of Fred Hutch Cancer Center 🇺🇸presenting POSTER board E31 Neoadjuvant Pembrolizumab and accelerated methotrexate, vinblastine, doxorubicin, cisplatin (aMVAC) in MI #BladderCancer Interview by our OncoAlert

Go meet and chat science with this superstar resident and incoming fellow MD Anderson Cancer Center. Andy Hahn Chad Tang, MD Alexander Sherry Matt Campbell MD, MS Mohammad Jad Moussa, MD, MSc Omar Alhalabi, MD Ashish M. Kamat, MD, MBBS Daniel Shapiro Brittney Cotta, MD Andrew Johns, MD

The ASCO Post ASCO Conquer Cancer, the ASCO Foundation KidneyCAN BCAN NCT Chapter @NIHDirector FDA Oncology ESMO - Eur. Oncology Society of Urologic Oncology NEJM

A few #GU25 highlights presenting our research on 🌀socioeconomic disparities, real-world patterns & outcomes in mUC 🌀tx sequencing for 2L mUC post EV/P Priyanka Chablani, MD, MS Petros Grivas Ali Khaki 🌀low-dose abi cost/adherence UIC Heme Onc Fellowship & 🌁 touring SF Caitlin Borne

Ruben Raychaudhuri Ali Khaki Fred Hutch Cancer Center Nicole D. Fleming MD OncoAlert Julie Gralow ASCO #GU25 Sarah P. Psutka MD MS Hsieh Lab Bárbara Melão, MD, PhD Dra. María Natalia Gandur Quiroga Uromigos UroToday.com aMVAC x4 (+G-CSF) + pembro x 3 neoadjuvant with pCR around 60% in MIBC with histology subtypes/variants (context AURA trial)

Wow. So true. Reason for this is we don't teach how to make medical decisions when there is residual uncertainty, and there always is. People fall back on pathophys which is a poor substitute for empirical thinking.

⭐ At ASCO #GU25, a group of experts discuss their survey-based study of treatment sequencing after 1L EV/pembro for la/mUC. 📺 Sharing their insights are Priyanka Chablani, MD, MS, Ali Khaki, Karine Tawagi MD, and Petros Grivas: buff.ly/4hShFFr

🚨 Proud to share our recent paper on virtual second opinions for cancer care Stanford Cancer Institute. Changes in management were recommended in >50% of cases. Many of these opinions were associated with: 1. de-escalation of care - e.g NOT recommending adjuvant chemotherapy for

This is a very positive step towards addressing regulatory capture. jamanetwork.com/journals/jamao… cancertherapyadvisor.com/home/cancer-to…

📢Fresh off the press! Happy to share our project on ICI in #urothelial cancer and histology subtypes. Many thanks to Petros Grivas Ali Khaki Rafee Talukder for the amazing guidance, and to all the collaborators Shilpa Gupta Vadim Koshkin MD joaquim bellmunt sciencedirect.com/science/articl…

Just presented by Max Diehn, MD/PhD at #AACR25 and published in Cancer Discovery: Mid-CRT ctDNA levels predict progression in early-stage NSCLC. Combining ctDNA with pre-CRT radiomic features improves outcome prediction. On-treatment biomarkers are key to enabling response-adapted therapies!

I’m proud to welcome Dr. Vinay Prasad, MD, MPH, as the new head of FDA’s Center for Biologics Evaluation & Research. With 500+ peer-reviewed publications and two books, Dr. Prasad brings the kind of scientific rigor, independence, and transparency we need at CBER—a significant

What an upgrade! Vinay Prasad MD MPH Secretary Kennedy Marty Makary MD, MPH

Such a well deserved recognition for Petros Grivas who has been incredibly dedicated to patient care and research! Fantastic role model! Mentees are very grateful Stepan M. Esagian, MD Phaedon Zavras Dimitra R. Bakaloudi MD, MS, MPA Panos Zoubourlis

Is the field of genitourinary oncology pivoting away from precision medicine -- and towards imprecision? In BJU International, Arash Rezazadeh and I cite two recent examples of TALAPRO-2 (for metastatic hormone resistant prostate cancer) and EV-302 (for advanced urothelial

Over the moon to receive the 2025 ASCO IDEA Award 🏆 Deeply grateful to my incredible mentors Yüksel Ürün Emre Yekedüz and colleagues at Ankara Üniversitesi for their unwavering support. Honored to stand among global inspring minds- energized, and hopeful for the future of onc🌍

TiP: TRIPLE-SWITCH -- Ph III RCT for adding Doce to ARPIs in mCSPC and subopt PSA resp UroToday.com #ASCO25 🔷n=830 🔷Subopt PSA resp: PSA ≥0.2 ng/mL after 6-12 mos ADT, ≥4 mos ARPI 🔷1:1 cont ADT + ARPI vs cont ARPI + ADT + Doce 🔷Prim EP: OS 🚨 Important RCT for subopt PSA

An amazing joint mtg of MOASC/ANCO at #ASCO25 bringing together so many friends & colleagues in #oncology from around #California! Was delighted to see the ASCO #Advocacy Team there, alongside Ali Khaki Nikita Baclig Neal S. Chawla Yulia Zektser, MD Alex Chehrazi-Raffle, MD Peter Zang

We’ve just kicked off! A fulfilling kind of exhaustion after going through all the GU posters — learning the art of critical thinking from our amazing IDEA mentor, Dr. Ali Khaki . Grateful for the insights and inspiration! 💡Conquer Cancer, the ASCO Foundation #ASCO25 #GUonc #MentorshipMatters

Naysayers predict doom at FDA w new leadership. Yet within weeks, Marty Makary MD, MPH Vinay Prasad MD MPH approve a new COVID vaccine and get a promise of a proper RCT And they speak w utter clarity and humility about net benefit/harms of *ALL* Medical Rxs. Can we now give them a chance?